glp 1 agonist black box warning What are experts learning about the long-term effects of GLP-1 medications? As more people stay on these medications for longer periods of time, researchers are paying closer attention to potential side effects FDA Ozempic Warning | Ozempic

Both conditions can cause abdominal distension, cramping, severe constipation, nausea, vomiting, dehydration, and inability to pass gas or stool

As seen below, the change in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS), reflecting physical limitations and symptoms, nearly doubled

Consult Pharm

According to NICE guideline NG28, GLP-1 receptor agonists should be considered when: Triple therapy (metformin and two other oral drugs) is not effective, not tolerated, or contraindicated The patient has a BMI 35 kg/m (or lower in people of Black, Asian and other minority ethnic groups) and specific obesity-related comorbidities The patient has a BMI 40% reduction in non-HDL cholesterol GLP-1 receptor agonist for glycaemic control and weight management (with secondary lipid benefits) Ezetimibe if non-HDL cholesterol reduction is insufficient Lifestyle interventions addressing diet, exercise, and weight Monitoring and follow-up are essential components of cholesterol management

The post hoc analysis of patients only from the PIONEER 6 (evaluating oral semaglutide) and SUSTAIN 6 (evaluating sc semaglutide) studies found a 23.8% reduction in MACEs associated with semaglutide treatment (HR 0.76, 95% CI 0.620.92), especially in the prevention of nonfatal stroke (HR 0.65, 95% CI 0.430.97) [62]

[24] [25] Manufacturers seeking to market products containing allulose must obtain authorisation demonstrating safety for human consumption